三元基因：重组人干扰素α1b喷雾剂获得批准通知书

Core Insights - The company has received approval from the National Medical Products Administration for its recombinant human interferon α1b spray (250,000 IU (25μg): 5ml/bottle) [1] - The approval notification revised the instructions, changing the usage warning from "for external use only, do not ingest, avoid contact with eyes" to "for external use only, strictly follow medical advice, avoid contact with eyes" [1] - The product was first approved for market in 2011 and is used to treat initial or recurrent facial herpes simplex caused by viruses, possessing both antiviral and immune-regulating properties [1] - In 2024, the product was successfully selected in the Jiangxi Provincial Medical Insurance Bureau's announcement of the "Interferon Interprovincial Alliance Centralized Procurement Selection Results," with a procurement period of four years [1]